Table 2:

Treatment history and response data for 3 patient

Case #	Prior therapies	Prior Radiation therapy (RT)	Type of immune checkpoint inhibitor (ICI)	Time elapsed betwee n last dose of thoraci c RT and initiatio n of ICI	Best response to ICI	Length of time on PD-1/PD- L1 therapy until development of pericarditis	Other irAEs	Therapy and Outcome	Histopathologic findings
1	Carboplatin + Pemetrexed + Bevacizumab × 3 cycles	Palliative RT to the right lung hilum (30 Gy) and right hip	PD-L1 inhibitor	14 days	Partial response (RECIST v1.1)	78 days	None	Presented with cardiac tamponade, and had cardiac arrest, did not respond to resuscitation and died	Complete pathologic response in hilar, carinal lymph nodes, right upper lobe of liver and pancreas, residual viable tumor identified in the left adrenal gland Cytology negative for malignant cells in pericardial effusion
2	Carboplatin + Pemetrexed × 6 cycles followed by Pemetrexed maintenance	Palliative RT (44Gy) to Right lung upper lobe	PD-L1 inhibitor + CTLA-4 inhibitor	145 days	Partial response (RECIST v1.1)	131 days	Grade 2 hypothyroidism (day 42)	Received pericardial drainage and pacemaker for arrhythmias, experienced further clinical decline and died 13 days after her presentation	Complete pathologic response in bilateral lung, periportal and peripancreatic LNs, only residual disease limited to thyroid gland (contiguous dissemination)
3	Cisplatin + Pemetrexed + Multikinase TKI × 6 cycles, followed by Pemetrexed + TKI	No prior RT	PD-L1 inhibitor	N/A	Stable disease	98 days*	None	Received pericardial window, with symptomatic improvement, PD after further 3 months of therapy with no additional toxicity after reintroduction.

(*trace pericardial effusion noted in an imaging study after 60 days of therapy).